Multiple sclerosis (MS) is an autoimmune disease of the brain and spinal cord that causes limb weakness and numbness, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems. The average life expectancy of someone living with MS is 10 years fewer than people without the disease. Current therapies are only partially effective and often have significant adverse side effects.
However, scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis in a new way that repairs MS-damaged nerve fibers and causes fewer side effects. One of the newly identified compounds, an existing drug to treat Parkinson's disease called benztropine, was highly effective in treating MS in mice, both alone and in combination with existing MS therapies.
However, scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis in a new way that repairs MS-damaged nerve fibers and causes fewer side effects. One of the newly identified compounds, an existing drug to treat Parkinson's disease called benztropine, was highly effective in treating MS in mice, both alone and in combination with existing MS therapies.
No comments:
Post a Comment